Cerus Corp. (NASDAQ:CERS) Receives $9.10 Average Target Price from Brokerages
Cerus Corp. (NASDAQ:CERS) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the firm. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.10.
A number of research firms have commented on CERS. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price target on shares of Cerus Corp. in a research report on Sunday, July 31st. FBR & Co restated an “outperform” rating and set a $10.00 price target on shares of Cerus Corp. in a research report on Tuesday, August 2nd. Robert W. Baird set a $10.00 price target on shares of Cerus Corp. and gave the stock a “buy” rating in a research report on Saturday, August 6th. Zacks Investment Research downgraded shares of Cerus Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Finally, BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Cerus Corp. in a research report on Monday, June 20th.
Cerus Corp. (NASDAQ:CERS) opened at 5.90 on Wednesday. The company’s 50 day moving average is $6.33 and its 200 day moving average is $6.23. The stock’s market cap is $605.98 million. Cerus Corp. has a 52 week low of $4.27 and a 52 week high of $7.64.
Cerus Corp. (NASDAQ:CERS) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. Cerus Corp. had a negative return on equity of 73.14% and a negative net margin of 189.29%. The company had revenue of $9.25 million for the quarter, compared to the consensus estimate of $8.88 million. During the same quarter last year, the firm posted ($0.17) earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Equities analysts predict that Cerus Corp. will post ($0.68) earnings per share for the current year.
In other news, CFO Kevin Dennis Green sold 17,150 shares of Cerus Corp. stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $6.80, for a total value of $116,620.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. 6.60% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in the company. Marathon Capital Management boosted its position in shares of Cerus Corp. by 61.9% in the second quarter. Marathon Capital Management now owns 17,000 shares of the company’s stock valued at $106,000 after buying an additional 6,500 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Cerus Corp. by 11.0% in the first quarter. Legal & General Group Plc now owns 17,612 shares of the company’s stock valued at $105,000 after buying an additional 1,744 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Cerus Corp. during the first quarter valued at about $110,000. Nuveen Fund Advisors LLC acquired a new position in shares of Cerus Corp. during the second quarter valued at about $129,000. Finally, AQR Capital Management LLC acquired a new position in shares of Cerus Corp. during the second quarter valued at about $181,000. 67.01% of the stock is currently owned by institutional investors.
Cerus Corp. Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corp. and related companies with MarketBeat.com's FREE daily email newsletter.